Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting NCT07714538

Breath Research Narrow Validation for Gastrointestinal Cancer Detection

Breath Research Narrow Validation for Gastrointestinal Cancer Detection — Recruiting • Oncology • NCT07714538.

📅 11 Sep 2026 ⏱ 3 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
NCT ID
NCT07714538
Sponsor
Imperial College London
Start
2026-07-26
ClinicaliQ Trial Snapshot
  • Breath Research Narrow Validation for Gastrointestinal Cancer Detection — Recruiting • Oncology • NCT07714538.
  • Sponsor: Imperial College London.

Verify eligibility, endpoints and current status on the original source registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

The investigators of this study are developing a simple breath test to help detect gastrointestinal (gut) cancers earlier, including cancers of the oesophagus (food pipe), stomach, pancreas, liver and bowel. These cancers often cause non-specific symptoms that are similar to benign conditions, making early diagnosis difficult. Delays between the onset of symptoms and referral for a diagnostic test such as an endoscopy or a scan, can allow the cancer to progress. The breath test detects small molecules called volatile organic compounds (VOCs) that are released in exhaled breath. Some of…

Eligibility Snapshot
  • : Adult participants ≥ 18 years old who meet at least one of the following criteria Colorectal arm: 1. Cancer: Histologically-confirmed CRC* 2. Control: Non-specific abdominal symptoms with normal or benign colonoscopy findings Pancreatic arm: 1. Cancer: Histologically-confirmed PDAC* 2. Control: Non-specific abdominal symptoms with a radiologically-normal pancreas Oesophagogastric arm: 1. Cancer: Histologically-confirmed OGC* 2. Control: Non-specific abdominal symptoms with normal or benign upper gastrointestinal endoscopy findings Oesophageal squamous arm: 1. Cancer: Histologically-confirmed OSCC* 2. Control: Non-specific abdominal symptoms with normal or benign upper gastrointestinal endoscopy findings Liver arm: 1. Cancer: Histologically- or radiologically-confirmed HCC or CCC* 2. Control: Non-specific abdominal symptoms with a radiologically-normal liver * Patients with suspected cancer (e.g. based on imaging) but who do not have histological confirmation prior to participating in the study may still be recruited and followed up to determine whether or not a diagnosis of cancer was subsequently confirmed.

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after an anti-androgen but not a taxane (terminated evaluation)
Oncology · 16 Jul 2026
Evaluation terminated – NICE discontinued appraisal of lutetium-177 vipivotide tetraxetan; this agent is not recommended for routine NHS use and should not…
View guideline →
Guideline
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer
Oncology · 16 Jun 2026
First-line treatment option: Cemiplimab combined with platinum-based chemotherapy is recommended by NICE for patients with untreated advanced non-small-cell lung cancer (NSCLC), offering…
View guideline →
Clinical Brief
AI to speed up cancer diagnosis for millions of NHS patients
Oncology · NHS England · 10 Jun 2026
AI technologies are being implemented across the NHS to accelerate cancer diagnosis and reduce current waiting times for patients requiring diagnostic assessment.…
View brief →
Clinical Brief
‘My cancer spread while I waited months for surgery’: The cost of England’s cancer wait times
Oncology · BBC Health · 10 Sep 2026
England's cancer surgery waiting times have deteriorated despite government initiatives aimed at improving them, with patients experiencing significant delays that may allow…
View brief →
Guideline
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for untreated advanced or recurrent endometrial cancer
Oncology · 09 Sep 2026
Durvalumab combined with platinum-based chemotherapy is the recommended first-line treatment for untreated advanced or recurrent endometrial cancer, with olaparib addition considered based…
View guideline →
Guideline
Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency
Oncology · 26 Aug 2026
Test for MSI-H/dMMR before treatment: All patients with advanced or recurrent endometrial cancer should undergo microsatellite instability or mismatch repair deficiency testing…
View guideline →